Annovis Bio, Inc. (ANVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc. on October 10, 2025. The Company, an emerging growth company incorporated in Delaware, is reporting the entry into a Material Definitive Agreement regarding a registered direct offering of its common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction with the following specific metrics:
- Securities Issued: 3,150,000 shares of Common Stock and pre-funded warrants to purchase up to 850,000 shares.
- Offering Price: $1.50 per share of Common Stock; $1.4999 per Pre-Funded Warrant.
- Gross Proceeds: Approximately $6.0 million (before deducting offering expenses).
- Placement Agent Fees: 7.0% of aggregate gross proceeds plus up to $50,000 for legal/clearing expenses.
- Placement Agent Warrants: Warrants to purchase 200,000 shares (5.0% of the offering) at an exercise price of $2.20 per share, exercisable immediately with a 5-year term.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures as this is a transactional report rather than a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. The Company plans to use the net proceeds for:
- Continued clinical development of its lead compound, Buntanetap, specifically for a Phase 3 study for Alzheimer's disease.
- Working capital and general corporate purposes.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The transaction supports the advancement of the Company's lead asset into Phase 3 trials, a critical milestone for Alzheimer's disease therapeutics.
Restrictions and Lock-ups:
- Variable Rate Transaction Lock-up: The Company is restricted from issuing shares or securities convertible into common stock involving a Variable Rate Transaction for one year following the Closing Date.
- Insider Lock-up: Directors and officers have agreed to a 45-day lock-up period following the Closing Date, restricting the sale or disposition of their shares.
Closing Conditions: The Offering is expected to close on or about October 14, 2025, subject to customary closing conditions.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received after deducting the 7.0% placement fee and other expenses.
- Confirm the specific timeline and enrollment status of the Phase 3 study for Buntanetap in Alzheimer's disease.
- Monitor the impact of the new share issuance (3.15 million shares) and warrants (1.05 million total underlying shares) on the Company's fully diluted share count.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any additional covenants or termination rights not summarized here.